NasdaqGM:MIRMBiotechs
Reassessing Mirum Pharmaceuticals (MIRM) Valuation After a Strong Multi‑Year Share Price Run
Mirum Pharmaceuticals (MIRM) has quietly rewarded patient investors, with the stock up roughly 9% over the past month and more than 90% this year. This invites a closer look at what the market is pricing in.
See our latest analysis for Mirum Pharmaceuticals.
That surge is not a one off. The 30 day share price return of 11.84 percent and year to date share price gain of 92.08 percent sit on top of a 3 year total shareholder return above 340 percent. This suggests momentum is still firmly with...